GLP-1 Medications and Pregnancy: What the Research Says

Disclaimer: This article is for informational purposes only and does not constitute medical advice. Always consult your healthcare provider before making changes to your treatment plan.

Current FDA Guidelines on GLP-1 and Pregnancy

The current position of the FDA and all GLP-1 medication manufacturers is unambiguous: these medications are not recommended for use during pregnancy. The prescribing information for semaglutide (Ozempic, Wegovy), tirzepatide (Mounjaro, Zepbound), and liraglutide (Saxenda, Victoza) all include explicit guidance to discontinue the medication when pregnancy is detected or planned. The basis for this recommendation is the absence of adequate well-controlled human studies demonstrating safety during pregnancy — not necessarily confirmed evidence of harm, but rather a fundamental insufficiency of data to establish safety with confidence.

Under the older FDA pregnancy category system (now largely replaced by the Pregnancy and Lactation Labeling Rule), GLP-1 medications were generally classified as Category C — meaning animal reproduction studies have shown adverse effects on the fetus, there are no adequate well-controlled human studies, and the potential benefits may warrant use in pregnant women despite potential risks in some specific clinical situations. This classification does not imply that these medications are teratogenic in humans, but it does indicate that caution is warranted and the default recommendation is to avoid use during pregnancy.

It is important to note that these guidelines are developed conservatively and reflect the principle that any uncertainty about fetal safety should resolve in favor of avoidance. The scientific community recognizes that conducting randomized controlled trials of medications in pregnant women is ethically constrained, which means the evidence base for any drug in pregnancy is limited. GLP-1 medications are relatively new in widespread use, and the accumulation of real-world safety data will continue to inform updated guidance in coming years.

What Animal Studies Showed

Reproductive toxicology studies conducted in animals — a required component of drug development before human approval — have produced findings that contributed to the current cautionary labeling for GLP-1 medications. In rodent and rabbit studies conducted at doses substantially higher than those used therapeutically in humans (often expressed as multiples of the human exposure), semaglutide demonstrated embryo-fetal toxicity including reduced fetal weight, skeletal abnormalities, and increased early pregnancy loss. Tirzepatide showed similar findings at high doses in animal models.

The critical context for interpreting these findings is the dose relationship. Adverse reproductive effects in animal studies are commonly observed only at doses far exceeding normal human therapeutic exposure. The relevance of high-dose animal findings to human outcomes at therapeutic doses is therefore limited — and regulatory agencies are well aware of this distinction. Nonetheless, because the precautionary principle calls for minimizing fetal exposure to any agent with potential for harm, animal data demonstrating toxicity at any dose is sufficient to generate a warning and a recommendation for avoidance.

Animal reproductive studies also evaluated GLP-1 medications's effects on lactation. Available data from animal studies suggest that semaglutide is present in rat milk, though whether this translates to clinically significant exposure in breastfed human infants is unknown. For this reason, GLP-1 medications are also currently not recommended during breastfeeding. Patients who are nursing or planning to breastfeed should discuss the timing of any GLP-1 treatment with their healthcare provider.

Limited Human Data: What We Know

Because of the rapid and widespread uptake of GLP-1 medications — particularly semaglutide for weight loss — an increasing number of women have become pregnant while on these medications, either because they were not aware of the recommendation to discontinue, or because conception occurred unexpectedly before a planned discontinuation. This real-world exposure has generated a growing body of case reports and registry data, though the numbers remain small and follow-up is limited.

The available human data — primarily case reports and the early output of pregnancy registries established by the manufacturers — do not reveal a clear pattern of harm or specific birth defects associated with first trimester GLP-1 exposure. However, the data are too limited in volume, duration, and systematic follow-up to draw any firm conclusions about safety. Absence of evidence is not evidence of absence, and the scientific and medical community is appropriately cautious about interpreting limited case data as reassurance.

Novo Nordisk and Eli Lilly have both established pregnancy exposure registries for semaglutide and tirzepatide respectively, and healthcare providers are encouraged to report cases of inadvertent pregnancy exposure. Over the next several years, this registry data will provide the most meaningful human safety signal for GLP-1 medications in pregnancy. Women who have become pregnant while on these medications are encouraged to enroll in these registries and to inform their obstetrician of their GLP-1 exposure history.

GLP-1 and PCOS: A Fertility Connection

Polycystic ovary syndrome (PCOS) is one of the most common hormonal disorders in women of reproductive age, affecting approximately 8-13% of this population. It is the leading cause of anovulatory infertility — infertility caused by irregular or absent ovulation. PCOS is strongly associated with insulin resistance and overweight or obesity, and weight loss is one of the most effective interventions for improving menstrual regularity, restoring ovulation, and improving fertility outcomes in women with PCOS.

GLP-1 medications' capacity to produce significant weight loss makes them potentially valuable for women with PCOS who are trying to conceive. Research in this area is still emerging, but preliminary evidence suggests that GLP-1-induced weight loss can restore ovulatory cycles, reduce androgen levels (the male hormones that are elevated in PCOS and disrupt ovulation), and improve the hormonal environment for conception. Some researchers have also proposed that GLP-1 receptors may have direct effects on ovarian function independent of weight loss, though this remains an area of active investigation.

The critical implication is that women with PCOS who start GLP-1 therapy may see their fertility improve as they lose weight — sometimes quite rapidly and unexpectedly. This represents both a potential benefit and a planning consideration: women who do not wish to become pregnant should ensure they have reliable contraception in place, particularly if their menstrual cycles were previously irregular and they had been relying on anovulation as a de facto form of contraception. Conversely, women with PCOS who do wish to conceive should work closely with their reproductive endocrinologist and GLP-1 prescriber to plan the appropriate timing of medication discontinuation.

When and How to Stop Before Pregnancy

The timing of GLP-1 medication discontinuation before attempting conception is an important planning consideration, primarily driven by each medication's pharmacokinetics — specifically its half-life. Semaglutide, the active ingredient in Ozempic and Wegovy, has an exceptionally long half-life of approximately one week. Standard pharmacological guidance suggests allowing five half-lives for a drug to be substantially cleared from the body, which for weekly semaglutide translates to approximately five weeks of clearance time. Current clinical guidance from most fertility and obesity medicine specialists recommends discontinuing semaglutide at least two months before attempting conception — a conservative timeframe that accounts for the full clearance period plus additional margin.

Tirzepatide (the active ingredient in Mounjaro and Zepbound) has a half-life of approximately five days, somewhat shorter than semaglutide, but the same general principle of allowing adequate clearance time applies. Liraglutide (Saxenda, Victoza), which is dosed daily rather than weekly, has a much shorter half-life and clears the system within days of discontinuation. Despite the different pharmacokinetics, most providers apply similar conservative discontinuation timelines across the GLP-1 class.

Patients planning pregnancy should raise this conversation with their GLP-1 prescriber well before they wish to start trying to conceive — ideally six months to a year in advance. This allows time to achieve weight loss goals that may improve fertility outcomes, plan the medication discontinuation timeline, establish the nutritional and lifestyle habits needed to maintain weight loss during the medication-free period, and optimize overall health before conception. Weight regain after stopping GLP-1 medications is a well-documented concern, and having a robust plan in place before stopping is far more effective than trying to manage weight regain reactively.

Contraception Considerations on GLP-1

Women of reproductive age who are on GLP-1 medications and do not wish to become pregnant should be aware of a potential interaction between GLP-1 therapy and oral contraceptives. GLP-1 receptor agonists slow gastric emptying and alter the absorption kinetics of orally administered medications. There is theoretical concern — and some supporting clinical data — that this slowed absorption could affect the bioavailability of oral contraceptive pills, potentially reducing their effectiveness.

The prescribing information for oral semaglutide (Rybelsus) explicitly notes that the medication affects the absorption of co-administered oral medications, and recommends taking oral contraceptives at least 30 minutes before Rybelsus. Injectable GLP-1 medications present a lower but still theoretically relevant concern given their systemic effects on gastric motility. Non-oral forms of contraception — including intrauterine devices (both hormonal and copper), implants, patches, rings, and injectable hormonal contraceptives — are not affected by GLP-1's impact on gastric absorption and are therefore preferred for women seeking the highest reliability.

Given the improved fertility that many women experience on GLP-1 therapy — particularly those with PCOS who may have had irregular cycles — the combination of a reliable contraceptive method and a clear pregnancy planning conversation with your healthcare provider is essential. Do not assume that irregular cycles before starting GLP-1 therapy will persist after weight loss begins. Many women are surprised by the return of regular ovulatory cycles during GLP-1 treatment, and being prepared for this fertility restoration is an important aspect of comprehensive care.